Can dapagliflozin protect breast cancer patients' hearts during chemo?
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if a diabetes medicine called dapagliflozin (also known as Farxiga) can protect the hearts of women with breast cancer while they receive anthracycline chemotherapy. You would take the medicine and have heart MRI scans to see if it helps prevent heart damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- You have been diagnosed with breast cancer.
- Your planned chemotherapy includes a total dose of at least 240 mg/m² of doxorubicin (a standard heart-related chemo).
- You do not have a pacemaker, defibrillator, or certain metal implants (you must be able to undergo an MRI heart scan).
- You have never had a heart attack, heart failure, heart surgery, or significant heart valve disease.
- Your kidneys are working well (no severe kidney failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug dapagliflozin can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. It aims to see if taking the drug during chemo helps keep your heart healthy.
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
This trial tests if the diabetes drug dapagliflozin can protect the heart in people with breast cancer receiving a type of chemotherapy called anthracyclines. You may be able to join if you are between 18 and 80, have stage I-III breast cancer, and are about to start anthracycline treatment within the next 60 days.
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
This trial tests whether two different medications (SGLT-2 inhibitor vs. DPP-4 inhibitor) can help prevent heart damage from certain chemotherapy drugs (anthracyclines) in women with breast cancer. It aims to protect your heart while you undergo cancer treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.